reports
- Maria Vara
BICO: Profitability gains and debt reduction amid persistent growth ch...
BICO closed Q4 2024 with strong profitability gains and a strengthened balance sheet, despite continued revenue challenges. Margin expansion and cost controls drove EBITDA growth, while a SEK394m convertible bond buyback reduced debt ahead of its 2026 maturity. However, soft demand in capital equip
- Maria Vara
BICO: navigating soft Q3 2024 demand with strategic focus
BICO reported Q3 2024 results showing continued profitability across all business segments, though overall sales and margins were affected by ongoing market challenges. Net sales declined by 15.7% YoY to SEK495.5m, with organic growth contracting by 12.6%. Gross margin improved slightly to 53.1% (5
- Maria Vara
BICO: optimises capital with SEK118m convertible bond buyback
Friday post-market, BICO announced the repurchased of SEK118m of its SEK1.5bn senior unsecured convertible bonds, originally issued in March 2021, at 83.63% of nominal value, amounting to SEK98.68m (excluding accrued interest). The buyback, enabled by the company’s liquidity position, reflects BICO
- Maria Vara
BICO: divests Nanoscribe for EUR26m in line with BICO 2.0 Strategy
BICO has agreed to sell Nanoscribe to LAB14 GmbH for an equity value of EUR26m (SEK294m), with the transaction set to close in Q4 2024. We are pleased to see the company executing the BICO 2.0 strategy shared during CMD 2024, which designates Nanoscribe as non-core due to its primary focus outside
- Maria Vara
BICO: CMD takeaways, a new vision amid tough market
Yesterday, BICO held a Capital Markets Day (CMD) where the new top executive management team provided an in-depth view of the renewed BICO 2.0 strategy. Aware of the Life Science (LS) Tools and Bioconvergence post-pandemic tough market conditions, the company's new vision focuses on Lab Automation
- Maria Vara
BICO: Q2 results show first signs of profitability, CMD in Sept
BICO has reported Q2 2024 results indicating a certain positive trend on profitability development with all segments reporting EBITDA positive for the first time despite sales remaining flatish. Net sales amounted to SEK 534m implying 5% QoQ growth yet a decrease of 1.3% YoY. The Biosciences segmen
- Maria Vara
BICO: profitability impacted by mixed sales in Q1 2024; CMD in Septemb...
BICO has reported Q1 2024 net sales amounting to SEK 510.3m (+2% vs. css) implying 4.4% YoY growth and organic growth of 4.7% (-1.1%). The Biosciences segment outperformed with net sales showing 36.3% organic growth to SEK 310m (SEK 230m), while Bioprinting and Bioautomation fell short of expectati
- Maria Vara
- Oscar Haffen Lamm
Coverage update
Given team and strategy changes, Oscar Haffen Lamm is now assuming coverage of Medincell, Camurus, Valneva, Aelis Pharma, Abivax, Calliditas, Egetis Therapeutics, Basilea, Geneuro, Achilles, Valerio, Innate Pharma, Morphosys, Inventiva Pharma, Vicore, DBV Technologies, and Genfit.Maria Vara is now
BSLN BASILEA PHARMACEUTICA AG
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ALMDT MEDIAN TECHNOLOGIES
EGTX EGETIS THERAPEUTICS AB
7CA CAMURUS AB
VICO VICORE PHARMA HOLDING AB
5142 ACHILLES CORP.
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
XVIVO XVIVO PERFUSION AB
GNRO GENEURO SA
BONEX BONESUPPORT HOLDING AB
MOR MORPHOSYS AG
MED MEDARTIS AG
MEDCL MEDINCELL SA
CALTX CALLIDITAS THERAPEUTICS AB
IVA INVENTIVA ADS
CLNK B CELLINK AB
GNFT GENFIT
AELIS AELIS FARMA SA
ONWD ONWARD OPPORTUNITIES LIMITED
ALONX ONXEO
ABVX ABIVAX
- Adam Karlsson
- Erik Cassel
- Jakob Lembke
- Adam Karlsson
- Erik Cassel
- Jakob Lembke
- Adam Karlsson
- Erik Cassel
- Jakob Lembke
- Adam Karlsson
- Erik Cassel
- Jakob Lembke
- Adam Karlsson
- Erik Cassel
- Gonzalo Artiach
- Jakob Lembke
- Morten Larsen
NOVO B NOVO NORDISK A/S CLASS B
SOBI SWEDISH ORPHAN BIOVITRUM AB
CRAD B C-RAD AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
SANION SANIONA AB
NANO NORDIC NANOVECTOR ASA
HUM HUMANA AB
ATT ATTENDO
AZN ASTRAZENECA PLC
BIOVIC B BIOVICA INTERNATIONAL AB
ONCO ONCOPEPTIDES AB
BONEX BONESUPPORT HOLDING AB
MCAP MEDCAP
PCIB PCI BIOTECH HOLDING ASA
ULTI ULTIMOVACS
BOUL BOULE DIAGNOSTICS AB
IVACC INTERVACC AB
QLINEA Q LINEA AB
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
CLNK B CELLINK AB
ABS ARCTIC BIOSCIENCE
NANEXA NANEXA AB
LINV LINC
IRLAB A IRLAB THERAPEUTICS
FLUO FLUOGUIDE AS
- Adam Karlsson
- Erik Cassel
- Jakob Lembke
- Adam Karlsson
- Erik Cassel
- Jakob Lembke
- Adam Karlsson
- Erik Cassel
- Jakob Lembke
- Adam Karlsson
- Erik Cassel
- Jakob Lembke
- Adam Karlsson
- Erik Cassel
- Jakob Lembke
- Adam Karlsson
- Erik Cassel
- Jakob Lembke
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.